Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Woman and Man Max 99 years
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schizophrenia
Primary Objective The primary objective is to evaluate the efficacy via the changes from baseline in the total Positive and Negative Syndrome Scale (PANSS) score of three fixed doses of JNJ-37822681 c...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Update Il y a 4 ans
Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects with Schizophrenia
To explore the response to flexible doses of paliperidone ER in acutely exacerbated subjects with schizophrenia. Response is defined as a decrease of at least 30% in total Positive and Negative Syndro...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Update Il y a 4 ans
An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age Protocol DORI-PED-1003; Phase 1
The primary objective of this study is to evaluate the pharmacokinetics of doripenem after single-dose administration of doripenem to infants (term and preterm), <12 weeks chronological age (CA). Safe...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Update Il y a 4 ans
A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation
The primary objective of this study is to determine the overall combined complete response rate (CR rate) (defined in this protocol as the combination of complete response [CR, including sCR and nCR])...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2